View Future GrowthCuorips 過去の業績過去 基準チェック /06Cuoripsの収益は年間平均-58.7%の割合で減少していますが、 Biotechs業界の収益は年間 増加しています。収益は年間14.3% 21.1%割合で 増加しています。主要情報-58.70%収益成長率-54.66%EPS成長率Biotechs 業界の成長31.91%収益成長率21.14%株主資本利益率-21.58%ネット・マージン-482.08%次回の業績アップデート13 Aug 2026最近の業績更新Reported Earnings • May 20Full year 2026 earnings released: JP¥124 loss per share (vs JP¥80.48 loss in FY 2025)Full year 2026 results: JP¥124 loss per share (further deteriorated from JP¥80.48 loss in FY 2025). Net loss: JP¥1.02b (loss widened 59% from FY 2025).Reported Earnings • Feb 16Third quarter 2026 earnings released: JP¥30.21 loss per share (vs JP¥18.10 loss in 3Q 2025)Third quarter 2026 results: JP¥30.21 loss per share (further deteriorated from JP¥18.10 loss in 3Q 2025). Net loss: JP¥249.0m (loss widened 72% from 3Q 2025).Reported Earnings • Jun 25Full year 2025 earnings released: JP¥80.48 loss per share (vs JP¥85.84 loss in FY 2024)Full year 2025 results: JP¥80.48 loss per share. Net loss: JP¥644.0m (loss widened 1.9% from FY 2024).お知らせ • Mar 27+ 3 more updatesCuorips Inc. to Report Q2, 2026 Results on Nov 13, 2025Cuorips Inc. announced that they will report Q2, 2026 results on Nov 13, 2025お知らせ • Aug 16Cuorips Inc. to Report Q3, 2025 Results on Feb 13, 2025Cuorips Inc. announced that they will report Q3, 2025 results on Feb 13, 2025お知らせ • Mar 02+ 2 more updatesCuorips Inc. to Report Fiscal Year 2024 Results on May 14, 2024Cuorips Inc. announced that they will report fiscal year 2024 results on May 14, 2024すべての更新を表示Recent updatesReported Earnings • May 20Full year 2026 earnings released: JP¥124 loss per share (vs JP¥80.48 loss in FY 2025)Full year 2026 results: JP¥124 loss per share (further deteriorated from JP¥80.48 loss in FY 2025). Net loss: JP¥1.02b (loss widened 59% from FY 2025).分析記事 • May 19Here's Why We're Not At All Concerned With Cuorips' (TSE:4894) Cash Burn SituationJust because a business does not make any money, does not mean that the stock will go down. For example, although...お知らせ • May 15Cuorips Inc., Annual General Meeting, Jun 25, 2026Cuorips Inc., Annual General Meeting, Jun 25, 2026.Reported Earnings • Feb 16Third quarter 2026 earnings released: JP¥30.21 loss per share (vs JP¥18.10 loss in 3Q 2025)Third quarter 2026 results: JP¥30.21 loss per share (further deteriorated from JP¥18.10 loss in 3Q 2025). Net loss: JP¥249.0m (loss widened 72% from 3Q 2025).New Risk • Feb 13New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 8.0% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (8.0% average weekly change). Minor Risks Less than 3 years of financial data is available. Revenue is less than US$5m (JP¥360m revenue, or US$2.3m).New Risk • Jan 07New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 5.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Less than 3 years of financial data is available. Share price has been volatile over the past 3 months (5.5% average weekly change). Revenue is less than US$5m (JP¥360m revenue, or US$2.3m).分析記事 • Jan 07Companies Like Cuorips (TSE:4894) Can Afford To Invest In GrowthEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...分析記事 • Aug 17Companies Like Cuorips (TSE:4894) Can Afford To Invest In GrowthEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Reported Earnings • Jun 25Full year 2025 earnings released: JP¥80.48 loss per share (vs JP¥85.84 loss in FY 2024)Full year 2025 results: JP¥80.48 loss per share. Net loss: JP¥644.0m (loss widened 1.9% from FY 2024).お知らせ • May 14Cuorips Inc., Annual General Meeting, Jun 19, 2025Cuorips Inc., Annual General Meeting, Jun 19, 2025.お知らせ • Mar 27+ 3 more updatesCuorips Inc. to Report Q2, 2026 Results on Nov 13, 2025Cuorips Inc. announced that they will report Q2, 2026 results on Nov 13, 2025New Risk • Nov 29New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Revenue has declined by 39% over the past year. Revenue is less than US$1m (JP¥23m revenue, or US$152k). Minor Risk Latest financial reports are more than 6 months old (reported March 2024 fiscal period end).分析記事 • Sep 18Here's Why We're Not At All Concerned With Cuorips' (TSE:4894) Cash Burn SituationEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...お知らせ • Aug 16Cuorips Inc. to Report Q3, 2025 Results on Feb 13, 2025Cuorips Inc. announced that they will report Q3, 2025 results on Feb 13, 2025分析記事 • May 22We Think Cuorips (TSE:4894) Can Easily Afford To Drive Business GrowthEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...New Risk • May 16New major risk - Revenue and earnings growthRevenue has declined by 39% over the past year. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If revenues are declining, then it is difficult for the company to prevent its earnings from declining as well. A trend of falling revenue can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (10% average weekly change). Revenue has declined by 39% over the past year. Revenue is less than US$1m (JP¥23m revenue, or US$149k).お知らせ • May 15Cuorips Inc., Annual General Meeting, Jun 26, 2024Cuorips Inc., Annual General Meeting, Jun 26, 2024.お知らせ • Mar 02+ 2 more updatesCuorips Inc. to Report Fiscal Year 2024 Results on May 14, 2024Cuorips Inc. announced that they will report fiscal year 2024 results on May 14, 2024New Risk • Jan 16New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.2% average weekly change). Earnings are forecast to decline by an average of 32% per year for the foreseeable future. Revenue is less than US$1m (JP¥38m revenue, or US$261k). Minor Risks Latest financial reports are more than 6 months old (reported March 2023 fiscal period end). Currently unprofitable and not forecast to become profitable over next 3 years (JP¥1.5b net loss in 3 years).お知らせ • Oct 25Cuorips Inc. to Report Q3, 2024 Results on Feb 13, 2024Cuorips Inc. announced that they will report Q3, 2024 results on Feb 13, 2024お知らせ • Oct 02Cuorips Inc. to Report Q2, 2024 Results on Nov 13, 2023Cuorips Inc. announced that they will report Q2, 2024 results on Nov 13, 2023New Risk • Jul 31New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 32% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings are forecast to decline by an average of 32% per year for the foreseeable future. Revenue is less than US$1m (JP¥38m revenue, or US$268k). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (JP¥1.5b net loss in 3 years). Market cap is less than US$100m (JP¥14.1b market cap, or US$99.3m).Board Change • Jun 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. was the last director to join the board, commencing their role in . The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.収支内訳Cuorips の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史TSE:4894 収益、費用、利益 ( )JPY Millions日付収益収益G+A経費研究開発費31 Mar 26212-1,0221,211031 Dec 25356-76573433430 Sep 25360-66162933430 Jun 25260-65245533431 Mar 25175-64442333431 Dec 2434-74050820931 Mar 2423-632388209質の高い収益: 4894は現在利益が出ていません。利益率の向上: 4894は現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: 4894の過去 5 年間の前年比収益成長率がプラスであったかどうかを判断するにはデータが不十分です。成長の加速: 4894の過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: 4894は利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( 4.3% ) と比較することは困難です。株主資本利益率高いROE: 4894は現在利益が出ていないため、自己資本利益率 ( -21.58% ) はマイナスです。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 18:54終値2026/05/22 00:00収益2026/03/31年間収益2026/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Cuorips Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Kyoichiro ShigemuraNomura Securities Co. Ltd.
Reported Earnings • May 20Full year 2026 earnings released: JP¥124 loss per share (vs JP¥80.48 loss in FY 2025)Full year 2026 results: JP¥124 loss per share (further deteriorated from JP¥80.48 loss in FY 2025). Net loss: JP¥1.02b (loss widened 59% from FY 2025).
Reported Earnings • Feb 16Third quarter 2026 earnings released: JP¥30.21 loss per share (vs JP¥18.10 loss in 3Q 2025)Third quarter 2026 results: JP¥30.21 loss per share (further deteriorated from JP¥18.10 loss in 3Q 2025). Net loss: JP¥249.0m (loss widened 72% from 3Q 2025).
Reported Earnings • Jun 25Full year 2025 earnings released: JP¥80.48 loss per share (vs JP¥85.84 loss in FY 2024)Full year 2025 results: JP¥80.48 loss per share. Net loss: JP¥644.0m (loss widened 1.9% from FY 2024).
お知らせ • Mar 27+ 3 more updatesCuorips Inc. to Report Q2, 2026 Results on Nov 13, 2025Cuorips Inc. announced that they will report Q2, 2026 results on Nov 13, 2025
お知らせ • Aug 16Cuorips Inc. to Report Q3, 2025 Results on Feb 13, 2025Cuorips Inc. announced that they will report Q3, 2025 results on Feb 13, 2025
お知らせ • Mar 02+ 2 more updatesCuorips Inc. to Report Fiscal Year 2024 Results on May 14, 2024Cuorips Inc. announced that they will report fiscal year 2024 results on May 14, 2024
Reported Earnings • May 20Full year 2026 earnings released: JP¥124 loss per share (vs JP¥80.48 loss in FY 2025)Full year 2026 results: JP¥124 loss per share (further deteriorated from JP¥80.48 loss in FY 2025). Net loss: JP¥1.02b (loss widened 59% from FY 2025).
分析記事 • May 19Here's Why We're Not At All Concerned With Cuorips' (TSE:4894) Cash Burn SituationJust because a business does not make any money, does not mean that the stock will go down. For example, although...
お知らせ • May 15Cuorips Inc., Annual General Meeting, Jun 25, 2026Cuorips Inc., Annual General Meeting, Jun 25, 2026.
Reported Earnings • Feb 16Third quarter 2026 earnings released: JP¥30.21 loss per share (vs JP¥18.10 loss in 3Q 2025)Third quarter 2026 results: JP¥30.21 loss per share (further deteriorated from JP¥18.10 loss in 3Q 2025). Net loss: JP¥249.0m (loss widened 72% from 3Q 2025).
New Risk • Feb 13New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 8.0% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (8.0% average weekly change). Minor Risks Less than 3 years of financial data is available. Revenue is less than US$5m (JP¥360m revenue, or US$2.3m).
New Risk • Jan 07New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 5.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Less than 3 years of financial data is available. Share price has been volatile over the past 3 months (5.5% average weekly change). Revenue is less than US$5m (JP¥360m revenue, or US$2.3m).
分析記事 • Jan 07Companies Like Cuorips (TSE:4894) Can Afford To Invest In GrowthEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
分析記事 • Aug 17Companies Like Cuorips (TSE:4894) Can Afford To Invest In GrowthEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Reported Earnings • Jun 25Full year 2025 earnings released: JP¥80.48 loss per share (vs JP¥85.84 loss in FY 2024)Full year 2025 results: JP¥80.48 loss per share. Net loss: JP¥644.0m (loss widened 1.9% from FY 2024).
お知らせ • May 14Cuorips Inc., Annual General Meeting, Jun 19, 2025Cuorips Inc., Annual General Meeting, Jun 19, 2025.
お知らせ • Mar 27+ 3 more updatesCuorips Inc. to Report Q2, 2026 Results on Nov 13, 2025Cuorips Inc. announced that they will report Q2, 2026 results on Nov 13, 2025
New Risk • Nov 29New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Revenue has declined by 39% over the past year. Revenue is less than US$1m (JP¥23m revenue, or US$152k). Minor Risk Latest financial reports are more than 6 months old (reported March 2024 fiscal period end).
分析記事 • Sep 18Here's Why We're Not At All Concerned With Cuorips' (TSE:4894) Cash Burn SituationEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
お知らせ • Aug 16Cuorips Inc. to Report Q3, 2025 Results on Feb 13, 2025Cuorips Inc. announced that they will report Q3, 2025 results on Feb 13, 2025
分析記事 • May 22We Think Cuorips (TSE:4894) Can Easily Afford To Drive Business GrowthEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
New Risk • May 16New major risk - Revenue and earnings growthRevenue has declined by 39% over the past year. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If revenues are declining, then it is difficult for the company to prevent its earnings from declining as well. A trend of falling revenue can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (10% average weekly change). Revenue has declined by 39% over the past year. Revenue is less than US$1m (JP¥23m revenue, or US$149k).
お知らせ • May 15Cuorips Inc., Annual General Meeting, Jun 26, 2024Cuorips Inc., Annual General Meeting, Jun 26, 2024.
お知らせ • Mar 02+ 2 more updatesCuorips Inc. to Report Fiscal Year 2024 Results on May 14, 2024Cuorips Inc. announced that they will report fiscal year 2024 results on May 14, 2024
New Risk • Jan 16New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.2% average weekly change). Earnings are forecast to decline by an average of 32% per year for the foreseeable future. Revenue is less than US$1m (JP¥38m revenue, or US$261k). Minor Risks Latest financial reports are more than 6 months old (reported March 2023 fiscal period end). Currently unprofitable and not forecast to become profitable over next 3 years (JP¥1.5b net loss in 3 years).
お知らせ • Oct 25Cuorips Inc. to Report Q3, 2024 Results on Feb 13, 2024Cuorips Inc. announced that they will report Q3, 2024 results on Feb 13, 2024
お知らせ • Oct 02Cuorips Inc. to Report Q2, 2024 Results on Nov 13, 2023Cuorips Inc. announced that they will report Q2, 2024 results on Nov 13, 2023
New Risk • Jul 31New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 32% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings are forecast to decline by an average of 32% per year for the foreseeable future. Revenue is less than US$1m (JP¥38m revenue, or US$268k). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (JP¥1.5b net loss in 3 years). Market cap is less than US$100m (JP¥14.1b market cap, or US$99.3m).
Board Change • Jun 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. was the last director to join the board, commencing their role in . The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.